Current News

PRESS RELEASE

Accera Inc. to Present at UBS Global Life Sciences Conference

Broomfield, CO, September 18, 2009 – Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced today that it will present at the UBS Global Life Sciences Conference September 21-23, 2009 in New York.

Steve Orndorff, Ph.D., founder, president and CEO, will provide a corporate overview of Accera and an update on Axona™ on Monday, September 21 at 11:30 a.m. EDT.

About Axona™
Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer’s disease. Dispensed by prescription, Axona targets the metabolic deficiencies and imbalances associated with Alzheimer’s disease by providing an alternative energy source for brain cells. With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer’s disease therapies. For more information about Axona, please visit www.about-axona.com or ask your physician.

About Accera, Inc.
Accera, Inc. is a privately held commercial-stage biotechnology company that developed and now markets Axona in the US. Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. In clinical trials, Axona has been shown to safely improve cognitive function and memory in AD patients. Axona addresses the hypometabolism or defective metabolism of glucose that occurs in those areas of the brain that are involved in Alzheimer’s disease. Accera engages in research, development and commercialization of other clinical applications for Axona, and has a wholly owned subsidiary, Neuera Pharmaceuticals, with a pipeline of small molecule drugs for neurodegenerative diseases.

###

Contacts: